ANZCTR search results

The overarching research question is ‘Does a therapist-assisted AI chatbot coach increase SA gamblers awareness of risky gambling behaviours and overcome barriers to seeking help?’ As a pilot study, we are not hypothesis testing, instead, we are interested in the acceptability and feasibility of providing the intervention, the AI chatbot online for South Australian gamblers. Acceptability of the chatbot and its content will be created and tested using a co-design process with gamblers and SA Gambling Help services. Our aims are to, engage and assess, engage and coach the AI chatbot, design content to target multiple gambling products through co-design, and finally pilot the chatbot by recruiting help seekers through social media.

High blood pressure, or hypertension, is a highly prevalent chronic disease, affecting 1 in 3 people in Australia. It is a disease where the blood inside the heart and blood vessels is pumped with more force than normal. This adds stress to these important organs, increasing the chance of having a heart attack or a stroke. We have shown that changes in the gut bacteria happen in hypertension. We think that these changes in the gut bacteria may disrupt intestinal permeability, also known as “leaky gut”. But we don’t know much about the relationship between blood pressure and leaky gut. This research will measure blood pressure and gut leakiness in people with normal and high blood pressure. By learning about the relationship between gut leakiness and blood pressure, we may be able to design drug and diet therapies that make the gut less leaky, to help people with high blood pressure. This research does not involve being given any treatments (e.g. drugs, special diets) for blood pressure.

Cardiovascular disease and its risk factors are prominent issues in T1D. There is a need to identify therapies that can address weight, glycaemia and other cardiometabolic indices in T1D. In T1D, whether tirzepatide, a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist improves weight, glycaemia and cardiometabolic health has not been previously studied. The TIRTLE study is a randomised controlled clinical trial in adults with type 1 diabetes.

The SOCRATES pilot study aims to assess the feasibility of randomising different Standard of Care (SoC) treatment options for a range of medical conditions listed below. 1) Recurrent glioblastoma 2) Non-metastatic castration-resistant prostate cancer 3) Metastatic castration-resistant prostate cancer 4) Metastatic castration-sensitive prostate cancer 5) Maintenance PARPinhibitor for primary ovarian cancer with BRCA mutation 6) Adjuvant Treatment for ER+ early breast cancer in post-menopausal women 7) HER2-negative advanced breast cancer after failure of anthracycline 8) Deep vein thrombosis (DVT) 9) Post Myocardial Infarction (MI) 10) People with office BP>120/80 and <150/90 in the setting of primary prevention of cardiovascular disease (CVD) 11) Non-valvular atrial fibrillation 12) Previous Myocardial Infarction (MI)/Stroke 13) Heart Failure with Reduced Ejection Fraction (HFrEF) without Diabetes mellitus (DM) 14) Hospital admission with first episode paroxysmal Atrial Fibrillation (AF) "Standard of care" refers to the treatment that a patient would usually be given for their health condition and is recommended by experts and scientific studies. There may be more than one SoC treatment for a medical condition. Who is it for? You can participate in this study if your medical condition is listed above and there is more than one standard of care options available for your health condition. Based on your own preference, you will either be a member of the randomised cohort or the non-randomised cohort. Participants in the randomised cohort will have their SoC option specified by a randomisation system. Participants in the non-randomised cohort will directly choose their SoC option in collaboration with their doctor. The study will also collect information on participant's experiences receiving the SoC option, as well as collect information on outcomes associated with the treatment they receive. The study plans to enrol approximately 200 participants in Australia.

The primary aim of the study is to determine the accuracy of POCUS, performed in the paediatric ED by ED physicians, for diagnosis of appendicitis. The study population will consist of patients 5-18 years old presenting to the WCH ED with suspicion of appendicitis over a 9 month period, with POCUS performed by 7 different ED physicians with differing levels of experience. Thus the primary interest are overall measures of diagnostic accuracy of POCUS when performed in the ED setting with formal scans.

OPTIMISM is a 4-week double-blind placebo-controlled feeding trial. All meals and snacks will be provided to participants for the duration of the study. In total, 22 healthy volunteers will be recruited along with 44 adults with a major depressive disorder (see linked record). Study visits will be conducted at baseline and week 4 at either the Health Education and Research Building (HERB), Barwon Health, Geelong, or at the Alfred Centre, Monash University, Melbourne.

This study is investigating the ability of the SeedTracker monitoring system to improve the accuracy of radiotherapy treatment delivered to the prostate, and any resultant changes in patient quality of life during and after radiotherapy. Who is it for? You may be eligible for this study if you are a prostate cancer patient receiving definitive radiotherapy to the prostate with current treatment protocol used within Liverpool and Macarthur cancer therapy centres. Study details The SeedTracker system will detect the position of radiopaque markers implanted in patients during pre-treatment position verification via monoscopic x-ray images acquired in real-time during treatment delivery. Radiation oncologists, Radiation Therapists and Physicists will use this data to monitor treatment margins accordingly throughout treatment, whilst monitoring the actual dose of radiation delivered. Participants will also be asked to complete quality of life questionnaires monitoring their bowel, urinary and sexual function during treatment and up to 5 years after completion of treatment. The researchers hope this trial will result in better outcomes for prostate cancer patients and lower side effects.

The aim of this study is to assess the effects and feasibility of the intervention for bedtime device use in new career starters. Using a three-arm randomised design, we will investigate the effects of intentions and habit-based approaches to reduce bedtime device use. The primary outcomes will be sleep duration, sleep quality, and bedtime device use. The secondary outcomes will be bedtime procrastination and excessive device use. We will further measure habit strength and motivation as mechanisms of change. Feasibility items to be assessed include daily survey completion rate, intervention attrition rate, as well as the effect of the intervention on outcome variables. The intervention will take place online, over a two-week period with a information video and coaching session on Zoom, as our needs assessment indicated this was the most commonly requested duration, format, and delivery method for an intervention program. It is hypothesised that: 1. Substitute and Prevent conditions will have a decrease in bedtime device use in week 2 compared to Control. 2. Substitute and Prevent conditions will have improved sleep outcomes in week 2 compared to week 1. 3. Substitute and Prevent conditions will have decreased bedtime procrastination scores, excessive device use and improved sleep quality at follow-up compared with baseline.

Prematurity remains common, and infants born prematurely have an increased risk of brain injury. “Encephalopathy of prematurity” refers to brain dysfunction and injury in preterm infants due to a variety of processes. It is known to be an important risk factor for adverse neurodevelopmental outcomes, however a thorough understanding of the causes, clinical presentation, evolution, and outcomes has not been fully established. The aim of this study is to better identify, understand and predict encephalopathy in preterm infants. This is an observational prospective cohort study that investigates babies born at less than 29 weeks’ gestation. Data will be collected on antenatal history, birth and resuscitation details, progress, clinical examinations and investigations in the Neonatal Intensive Care Unit (NICU). For the study, participants will undergo additional periods of brain monitoring and brain imaging. Video recordings will also be taken of routine neurological examinations at certain timepoints. Data will then be collected from routine developmental progress. Data will then be collected from the routine neurodevelopmental follow-up appointments at 12-14 weeks and 24-30 months corrected age. Outcomes of the study have the potential to improve the identification and care of infants at risk of encephalopathy, and better understand their prognosis. A better understanding of the condition may pave the way for future studies on targeted therapies to improve neonatal neurological and developmental outcomes.

This is a open-label, randomized, 3-period, 6-sequence crossover study to determine the relative bioavailability of two formulations (10% and 30%) of radiprodil under fasted and fed conditions in healthy adult participants. Radiprodil may be indicated for use in patients with GRIN related disorders, but a trial of the drug in healthy volunteers is needed before trials in patients with GRIN related disorders can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 55 years and are in good general health without a clinically significant medical history. Study details: All healthy volunteer participants who choose to enrol in this study will receive a single dose of radiprodil over 3 separate periods under fasted and fed conditions. All participants will have their vital signs checked (heart rate, blood pressure, temperature, etc), and will provide blood and urine samples for testing. The data generated in this study will inform the design of future clinical studies and to select the dose(s) for future studies in patients with GRIN related disorders.